Evidence map›Paper›PMID 41204954›Full record

ArticleNeuroradiology2025

MRI-based glymphatic markers and composite scoring for the discrimination of mild cognitive impairment in cerebral small vessel disease.

Min Xu, Boyu Zhang, Haixia Mao, Yachen Shi, Lin Ma, Jiayi Yang, Mingyu Li, Feng Wang, He Wang, Xiangming Fang

Abstract read
PubMed Publisher
In one paragraph

Article in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Min XuThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Boyu Zhang *Shanghai Fourth People's Hospital Affliated to Tongji University School of Medicine, Shanghai, China.
Haixia MaoThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Yachen ShiThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Lin MaThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Jiayi Yang *The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Mingyu LiThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China.
Feng WangThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China. wangfeng_njmu@163.com.
He WangShanghai Fourth People's Hospital Affliated to Tongji University School of Medicine, Shanghai, China. hewang@fudan.edu.cn.
Xiangming FangThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, China. xiangming_fang@njmu.edu.cn.

Funding

Medical Expert Team Program of Wuxi Taihu Talent Plan THRC-TD-YXYXK-2021National Natural Science Foundation of China 81271629Natural Science Foundation of Jiangsu Province BK20191143Wuxi Medical Innovation Team Program CXTD2021002
6 · The paper itself

Abstract

purposeGlymphatic system (GS) alterations has been increasingly associated with cognitive impairment in cerebral small vessel disease (CSVD). Comprehensive and quantifiable markers of GS function remain limited.

methodsGS was assessed using three non-invasive MRI-based metrics including analysis along perivascular space (ALPS) index, coupling between global blood-oxygen-level-dependent (gBOLD) signal and cerebrospinal fluid (CSF) movement, and choroid plexus volume (CPV). Correlations between GS metrics and CSVD markers were examined, along with their associations with cognition. A weighted glymphatic composite score (GCS) was subsequently derived based on relative cognitive contributions.

resultsWe recruited 350 participants (65.53 ± 7.65 years), with 160 CSVDs and 190 healthy controls (HC). Compared with CSVD-normal cognition (CSVD-NCI), the CSVD-mild cognitive impairment (CSVD-MCI) group exhibited significantly lower ALPS indices and higher CPV (p < 0.001). CSVD markers including periventricular (β = -0.350; β = 0.404) and deep (β = -0.330; β = 0.324) white matter hyperintensities, microbleeds (β= -0.255; β = 0.191), lacunes (β = -0.194; β = 0.177), and perivascular spaces (β = -0.335; β = 0.390) were associated with ALPS index and CPV (p < 0.01).Linear analyses revealed a significant interaction between ALPS and CSVD on cognition (p < 0.05), which remained robust after further adjustment for vascular risk factors. Compared to CSVD-NCI, CSVD-MCI exhibited significantly lower GCS (p < 0.05). The GCS was significantly associated with MCI status after adjustment for clinical factors (OR = 0.31, p = 0.024).

conclusionsCombining multiple GS-related MRI markers into a composite index effectively reflects cognitive status in CSVD and may serve as a non-invasive biomarker for CSVD-MCI discrimination.

Indexed as

Cerebral Small Vessel DiseasesCognitive DysfunctionGlymphatic SystemMagnetic Resonance ImagingAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedBiomarkersCerebral small vessel diseaseComposite scoreGlymphatic systemMild cognitive impairmentNeuroimaging

Identifiers

PMID41204954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.